浙江我武生物科技股份有限公司 对外投资决策制度 （2025 年 10 月） 第一章 总 则 本条所称"对外投资"不包括公司的下列活动：购买与日常经营相关的原材料、燃 料和动力（不含资产置换中涉及购买、出售此类资产）；出售产品、商品等与日常 经营相关的资产（不含资产置换中涉及购买、出售此类资产）；其他属于公司的主 营业务活动的事项。 第三条 根据国家对投资行为管理的有关要求，需要报政府部门审批的，应履行必要的报批 1 第一条 为了加强浙江我武生物科技股份有限公司（以下简称"公司"）投资活动的管理， 规范公司的投资行为，建立有效的投资风险约束机制，保护公司和股东的利益，根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上 市规则》"）和《浙江我武生物科技股份有限公司章程》（以下简称"《公司章程》"）， 特制定本制度。 第二条 本制度所称对外投资系指： (一) 购买或者出售资产； (二) 对外投资（含委托理财，对子公司投资等，设立或者增资全资子公司除 外）； (三) 租入或者租出资产； (四) 签订管理方 ...

浙江我武生物科技股份有限公司 独立董事制度 （2025 年 10 月） 第一章 总则 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或者 个人的影响。 第三条 公司董事会成员中应当至少包括三分之一独立董事，其中至少包括一名会计专 业人士。 独立董事应当在审计委员会、提名委员会、薪酬和考核委员会成员中过半数， 并担任召集人。其中，审计委员会成员应当为不在公司担任高级管理人员的董 事，审计委员会的召集人应当为会计专业人士。 第四条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、行政法规、 中国证券监督管理委员会规定、深圳证券交易所业务规则和《公司章程》的规 定，认真履行职责，在董事会中发挥参与决策、监督制衡、专业咨询作用，维 前款第四项至第六项中的公司控股股东、实际控制人的附属企业，不包括《上 市规则》规定的与公司不构成关联关系的附属企业。 第一款中"直系亲属"是指配偶、父母、子女；"主要社会关系"是指兄弟姐 妹、兄弟姐妹的配偶、配偶的父母、配偶的兄弟姐妹、子女的配偶、子女配偶 的父母等；"重大业务往来"是指根据《上市规则》及深圳证券交易所其他相 关规定或者《公司章程》规定需提交股东 ...

浙江我武生物科技股份有限公司 防范控股股东及关联方占用公司资金管理制度 （2025 年 10 月） 第一章 总则 1 第一条 为建立防止控股股东及关联方占用浙江我武生物科技股份有限公司（以 下简称"公司"）资金的长效机制，杜绝控股股东及关联方资金占用行 为的发生，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"、《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》、《深圳证券交 易所创业板股票上市规则》（以下简称"《上市规则》"）、《深圳证券交易 所创业板上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《规范运作》"）等法律法规、部门规章、规范性文件和《浙 江我武生物科技股份有限公司章程》（以下简称"《公司章程》"），制定 本制度。 第二条 公司及纳入合并报表范围的子公司与公司控股股东、实际控制人及关联 方之间的资金往来适用本制度。 第三条 本制度所称资金占用包括但不限于以下方式： （一）经营性资金占用：指控股股东、实际控制人及关联方通过采购、 销售等生产经营环节的关联交易产生的资金占用。 （二）非经营性资金 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-037 号 浙江我武生物科技股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江我武生物科技股份有限公司（以下简称"公司"）第五届董事会第十四次会议 通知于 2025 年 10 月 13 日以邮件方式发出。会议于 2025 年 10 月 23 日在公司上海分公 司会议室（上海市钦江路 333 号 40 号楼 5 楼）以现场方式召开。会议应出席董事 6 人， 实际出席董事 6 人。会议由董事长胡赓熙先生召集并主持，公司部分高级管理人员列席 了会议。本次会议的召集、召开符合《中华人民共和国公司法》等有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 1. 审议通过《公司 2025 年第三季度报告》 《公司 2025 年第三季度报告》的编制和审核程序符合法律、行政法规和中国证监 会的规定，报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、 误导性陈述或者重大遗漏。 本议案报告中的财务信息已经审计委员会 ...

证券代码：300357 证券简称：我武生物 公告编号：2025-039 号 浙江我武生物科技股份有限公司 关于 2025 年第三季度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 审议程序 浙江我武生物科技股份有限公司（以下简称"公司"）于 2025年10月23日 召开了第五届董事会第十四次会议，以6票赞成、0票反对、0票弃权的表决结果 审议通过了《公司2025年第三季度利润分配的方案》。本次利润分配方案尚需提 交公司股东会审议。 二、 利润分配方案的基本情况 1. 本次利润分配为公司2025年第三季度利润分配。 2. 公司法定公积金累计额已超过公司注册资本的50%，根据《公司法》和 《公司章程》的相关规定，公司不再提取法定公积金。根据公司2025年第三季度 财务报表（未经审计），2025年1-9月合并报表归属于上市公司股东的净利润为 344,866,533.27 元 ； 截 至 2025 年 9 月 30 日 ， 公 司 合 并 报 表 未 分 配 利 润 1,713,212,446.57元，母公司报表未分配利润1,992,117, ...

我武生物公告，第三季度营收为3.69亿元，同比增长22.64%；净利润为1.68亿元，同比增长36.44%。前 三季度营收为8.53亿元，同比增长16.86%；净利润为3.45亿元，同比增长26.67%。 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥369,123,847.45, representing a 22.64% increase year-over-year[5] - Net profit attributable to shareholders was ¥167,857,811.64, up 36.44% compared to the same period last year[5] - The basic earnings per share for the quarter was ¥0.3206, reflecting a 36.43% increase year-over-year[5] - Total operating revenue increased to ¥853,360,357.81, up from ¥730,238,304.07, representing a growth of approximately 16.83% year-over-year[18] - Net profit for the period reached ¥335,236,989.97, compared to ¥262,498,098.02 in the previous period, marking a growth of approximately 27.67%[19] - Total comprehensive income for the period attributable to the parent company was CNY 344,862,486.72, up from CNY 272,252,571.86 in the previous period, representing a growth of approximately 26.67%[20] - Basic and diluted earnings per share increased to CNY 0.6587 from CNY 0.5200, reflecting a rise of 26.54%[20] Assets and Equity - Total assets at the end of the reporting period amounted to ¥2,893,213,877.24, a 6.80% increase from the end of the previous year[5] - The company's total equity attributable to shareholders rose to ¥2,635,739,108.73, an increase of 11.98% from the previous year[5] - The company's total assets amounted to ¥2,893,213,877.24, an increase from ¥2,709,124,934.20, indicating a growth of about 6.79%[17] - The total equity attributable to shareholders increased to ¥2,635,739,108.73 from ¥2,353,706,702.01, reflecting a growth of approximately 11.97%[17] Cash Flow - Cash flow from operating activities increased by 79.11% to ¥286,891,077.51 year-to-date[10] - Cash inflow from operating activities totaled CNY 870,623,729.48, compared to CNY 643,008,995.35 in the previous period, marking an increase of 35.43%[20] - Net cash flow from operating activities was CNY 286,891,077.51, up from CNY 160,173,375.99, indicating a growth of 79.06%[20] - Cash inflow from investment activities was CNY 744,697,126.87, significantly higher than CNY 174,106,415.76 in the previous period, representing an increase of 327.36%[21] - Net cash flow from investment activities was -CNY 150,256,198.08, an improvement from -CNY 544,564,451.38, showing a reduction in cash outflow by 72.55%[21] - Cash inflow from financing activities was CNY 20,000,000.00, up from CNY 2,762,114.33, reflecting a growth of 624.57%[21] - Net cash flow from financing activities was -CNY 127,817,678.53, slightly worse than -CNY 120,336,902.70 in the previous period, indicating a marginal increase in cash outflow by 6.18%[21] Product Performance - The sales revenue from the "Dust Mite Drops" product was ¥794,221,951.72, a 13.38% increase year-over-year[9] - The revenue from "Artemisia Flower Pollen Sublingual Drops" surged by 117.58% to ¥44,756,599.93[9] Shareholder Information - Total number of common shareholders at the end of the reporting period is 32,427[12] - Zhejiang Wawu Management Consulting Co., Ltd. holds 38.86% of shares, totaling 203,454,131 shares[12] - The number of shares held by the top ten shareholders reflects significant concentration, with the top shareholder holding nearly 39%[12] Liabilities - Current liabilities decreased to ¥119,952,859.31 from ¥182,583,159.67, a reduction of approximately 34.29%[17] - Non-current liabilities decreased to ¥42,028,479.16 from ¥67,712,099.18, showing a decline of about 38.06%[17] Research and Development - The company completed a clinical trial for "Artemisia pollen allergen sublingual drops" in July 2025, providing evidence for long-term efficacy[13] - In August 2025, the company initiated a Phase I clinical study for "Dermatitis Diagnostic Patch 02" in Jining[13] - A Phase I clinical study for "Aspergillus niger puncture solution" was completed in September 2025, with a summary report obtained[13] Financial Position - The company's cash and cash equivalents decreased to ¥1,055,130,256.56 from ¥1,118,840,884.89[15] - Accounts receivable increased to ¥263,387,763.43 from ¥153,014,697.27[15] - The trading financial assets increased to ¥286,816,966.83 from ¥196,090,885.90[15] Audit Information - The company did not undergo an audit for the third quarter financial report[22]

Core Viewpoint - Iwubio experienced a decline of 3.18% in stock price on October 22, with a trading volume of 323 million yuan, indicating potential market volatility and investor sentiment shifts [1] Financing Summary - On October 22, Iwubio had a financing buy-in amount of 38.93 million yuan and a financing repayment of 53.99 million yuan, resulting in a net financing outflow of 15.07 million yuan [1] - The total financing and securities lending balance for Iwubio reached 430 million yuan, with the financing balance accounting for 2.58% of the circulating market value, indicating a high level of financing activity compared to the past year [1] - The company had a securities lending repayment of 2,100 shares and a securities lending sell-out of 1,100 shares, with a sell-out amount of 34,800 yuan calculated at the closing price [1] Business Performance - As of June 30, Iwubio reported a total of 34,600 shareholders, a decrease of 3.53% from the previous period, while the average circulating shares per person increased by 3.66% to 13,999 shares [2] - For the first half of 2025, Iwubio achieved an operating income of 484 million yuan, representing a year-on-year growth of 12.81%, and a net profit attributable to shareholders of 177 million yuan, up 18.61% year-on-year [2] Dividend and Shareholding Information - Since its A-share listing, Iwubio has distributed a total of 913 million yuan in dividends, with 317 million yuan distributed over the past three years [3] - As of June 30, 2025, among the top ten circulating shareholders, the China National Securities Bio-Medical Index A (161726) held 4.69 million shares, a decrease of 188,000 shares from the previous period, while Hong Kong Central Clearing Limited held 4.11 million shares, down 491,800 shares [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Investment Rating - The report maintains a positive outlook on the innovative drug and medical device industry, highlighting key targets for investment [5][24]. Core Insights - The innovative drug sector is experiencing high growth, with a focus on companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. The report emphasizes the potential for value re-evaluation in these firms [5][24]. - Recent business development (BD) deals in the innovative drug sector are expected to catalyze market activity, with notable transactions including Jiangsu Heng Rui Medicine's agreement with Kite for a $1.20 billion upfront payment, potentially reaching $15.20 billion in total [5][24]. - The A-share pharmaceutical sector underperformed the broader market in the third week of October 2025, with the Shanghai Composite Index falling by 1.5% and the SW Biopharma index declining by 2.5% [7][18]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Medical Devices - The report emphasizes the high growth potential in innovative drugs, with key investment targets including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. Related targets include CSPC Innovation Pharmaceutical [5][24]. 2. A-Share Pharmaceutical Sector Performance - In the third week of October 2025, the A-share pharmaceutical sector saw a decline of 2.5%, underperforming the Shanghai Composite Index, which fell by 1.5%. The report notes that the sector's premium relative to all A-shares is currently at a normal level, with a relative premium rate of 74.5% [7][14][21]. 3. Hong Kong and U.S. Pharmaceutical Sector Performance - The report indicates that the Hong Kong and U.S. pharmaceutical sectors also underperformed, with the Hang Seng Healthcare index dropping by 5.8% and the S&P 500 Healthcare index increasing by only 0.7% during the same period [18][24].